IMR Press / EJGO / Volume 40 / Issue 5 / DOI: 10.12892/ejgo4615.2019
Pazopanib for the treatment of gynecological malignancies
Show Less
1 Academic Unit of Obstetrics and Gynaecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy
2 Department of Surgical and Diagnostic Science, Genova, Italy
3 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, Genova, Italy
Eur. J. Gynaecol. Oncol. 2019, 40(5), 702–708;
Published: 10 October 2019

Angiogenesis is a well-established therapeutic target in gynecological malignancies. Vascular growth factor (VEGF) plays a critical role in angiogenesis, but also other growth factor receptors, such as platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF), have been demonstrated to contribute to it. Pazopanib is an oral multi-targeted tyrosine kinase inhibitor (TKI) under clinical investigation in late clinical trials for the treatment of gynecological cancers. Moreover, in 2012 the Food and Drug Administration (FDA) approved pazopanib for the treatment of advanced soft-tissue sarcomas, including uterine leiomyosarcoma. This review aims to provide a complete and updated overview on results of clinical studies of pazopanib for the treatment of gynecological malignancies, highlighting the ongoing trials.

Vascular growth factor (VEGF)
platelet-derived growth factor (PDGF)
Figure 1.
Back to top